153 related articles for article (PubMed ID: 16160649)
1. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour.
Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Tsutsui K; Wakabayashi H; Ohkawa M
Nucl Med Commun; 2005 Oct; 26(10):895-901. PubMed ID: 16160649
[TBL] [Abstract][Full Text] [Related]
2. Comparison of early and delayed FDG PET for evaluation of biliary stricture.
Nishiyama Y; Yamamoto Y; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Ohkawa M
Nucl Med Commun; 2007 Dec; 28(12):914-9. PubMed ID: 18090217
[TBL] [Abstract][Full Text] [Related]
3. Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
Yamamoto Y; Kameyama R; Togami T; Kimura N; Ishikawa S; Yamamoto Y; Nishiyama Y
Nucl Med Commun; 2009 Jan; 30(1):25-9. PubMed ID: 19306511
[TBL] [Abstract][Full Text] [Related]
4. Dual-phase 18F-FDG PET/CT imaging in the characterization of pancreatic lesions: does it offer prognostic information?
Santhosh S; Mittal BR; Bhasin D; Rana SS; Bhattacharya A; Srinivasan R; Nada R; Gupta R
Nucl Med Commun; 2014 Oct; 35(10):1018-25. PubMed ID: 25023999
[TBL] [Abstract][Full Text] [Related]
5. Dual-time-point FDG PET for the evaluation of locoregional lymph nodes in thoracic esophageal squamous cell cancer.
Hu Q; Wang W; Zhong X; Yuan S; Fu Z; Guo H; Yu J
Eur J Radiol; 2009 May; 70(2):320-4. PubMed ID: 18602239
[TBL] [Abstract][Full Text] [Related]
6. Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma.
Nishiyama Y; Yamamoto Y; Fukunaga K; Kimura N; Miki A; Sasakawa Y; Wakabayashi H; Satoh K; Ohkawa M
J Nucl Med; 2006 Apr; 47(4):633-8. PubMed ID: 16595497
[TBL] [Abstract][Full Text] [Related]
7. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
[TBL] [Abstract][Full Text] [Related]
8. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer.
Nishiyama Y; Yamamoto Y; Kimura N; Ishikawa S; Sasakawa Y; Ohkawa M
Ann Nucl Med; 2008 May; 22(4):245-50. PubMed ID: 18535874
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
[TBL] [Abstract][Full Text] [Related]
10. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
11. Dual-time-point FDG PET/CT: Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer?
Kim DW; Kim WH; Kim CG
Nucl Med Mol Imaging; 2012 Sep; 46(3):196-200. PubMed ID: 24900060
[TBL] [Abstract][Full Text] [Related]
12. Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer.
Lyshchik A; Higashi T; Nakamoto Y; Fujimoto K; Doi R; Imamura M; Saga T
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):389-97. PubMed ID: 15372209
[TBL] [Abstract][Full Text] [Related]
13. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
14. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
Conrad GR; Sinha P
Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
[TBL] [Abstract][Full Text] [Related]
15. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma.
Lin WY; Tsai SC; Hung GU
Nucl Med Commun; 2005 Apr; 26(4):315-21. PubMed ID: 15753790
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5.
Hashimoto Y; Tsujikawa T; Kondo C; Maki M; Momose M; Nagai A; Ohnuki T; Nishikawa T; Kusakabe K
J Nucl Med; 2006 Mar; 47(3):426-31. PubMed ID: 16513611
[TBL] [Abstract][Full Text] [Related]
17. PET evaluation of fatty tumors in the extremity: possibility of using the standardized uptake value (SUV) to differentiate benign tumors from liposarcoma.
Suzuki R; Watanabe H; Yanagawa T; Sato J; Shinozaki T; Suzuki H; Endo K; Takagishi K
Ann Nucl Med; 2005 Dec; 19(8):661-70. PubMed ID: 16444991
[TBL] [Abstract][Full Text] [Related]
18. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients.
Lemke AJ; Niehues SM; Hosten N; Amthauer H; Boehmig M; Stroszczynski C; Rohlfing T; Rosewicz S; Felix R
J Nucl Med; 2004 Aug; 45(8):1279-86. PubMed ID: 15299049
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
20. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]